Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 183

Similar articles for PubMed (Select 22422493)

1.

Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-α blockers.

Di Minno MN, Iervolino S, Peluso R, Russolillo A, Lupoli R, Scarpa R, Di Minno G, Tarantino G; CaRRDS Study Group.

J Rheumatol. 2012 May;39(5):1042-6. doi: 10.3899/jrheum.111391. Epub 2012 Mar 15.

PMID:
22422493
2.

The impact of concomitant diffuse idiopathic skeletal hyperostosis on the achievement of minimal disease activity in subjects with psoriatic arthritis.

Pappone N, Di Minno MN, Iervolino S, Lupoli R, Mader R, Zincarelli C, Peluso R.

Rheumatol Int. 2015 Jun 6. [Epub ahead of print]

PMID:
26048625
3.

Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment.

Janta I, Martínez-Estupiñán L, Valor L, Montoro M, Baniandres Rodriguez O, Hernández Aragüés I, Bello N, Hernández-Flórez D, Hinojosa M, Martínez-Barrio J, Nieto-González JC, Ovalles-Bonilla JG, González CM, López-Longo FJ, Monteagudo I, Naredo E, Carreño L.

Clin Rheumatol. 2015 May;34(5):935-42. doi: 10.1007/s10067-015-2880-7. Epub 2015 Jan 31.

PMID:
25636779
4.

Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.

Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A, Lapadula G.

Scand J Rheumatol. 2015 May;44(3):192-9. doi: 10.3109/03009742.2014.962081. Epub 2015 Jan 7.

PMID:
25564882
5.

Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis.

Haddad A, Thavaneswaran A, Ruiz-Arruza I, Pellett F, Chandran V, Cook RJ, Gladman DD.

Arthritis Care Res (Hoboken). 2015 May;67(6):842-7. doi: 10.1002/acr.22529.

PMID:
25469741
6.

Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.

Yonenaga T, Saeki H, Nakagawa H, Fukuchi O, Umezawa Y, Hayashi M, Ito T, Yanaba K, Tojyo S, Fukuda K.

J Dermatol. 2015 Jan;42(1):49-55. doi: 10.1111/1346-8138.12708. Epub 2014 Nov 26.

PMID:
25425546
7.

Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.

Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O.

J Rheumatol. 2015 Jan;42(1):73-8. doi: 10.3899/jrheum.140685. Epub 2014 Nov 15.

PMID:
25399390
8.

Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Costa L, Caso F, Ramonda R, Del Puente A, Cantarini L, Darda MA, Caso P, Lorenzin M, Fiocco U, Punzi L, Scarpa R.

Immunol Res. 2015 Feb;61(1-2):147-53. doi: 10.1007/s12026-014-8595-z.

PMID:
25395342
9.

Self-reported adherence to a home-based exercise program among patients affected by psoriatic arthritis with minimal disease activity.

Chimenti MS, Triggianese P, Conigliaro P, Santoro M, Lucchetti R, Perricone R.

Drug Dev Res. 2014 Nov;75 Suppl 1:S57-9. doi: 10.1002/ddr.21197.

PMID:
25381979
10.

Thalassemic trait prevalence in patients affected by psoriatic arthritis in anti-TNF treatment.

Atteno M, Costa L, Vitiello M, Caso F, Sarnelli G, Del Puente A, Scarpa R.

Drug Dev Res. 2014 Nov;75 Suppl 1:S20-2. doi: 10.1002/ddr.21188.

PMID:
25381968
11.

Complex role of TNF variants in psoriatic arthritis and treatment response to anti-TNF therapy: evidence and concepts.

Hüffmeier U, Mössner R.

J Invest Dermatol. 2014 Oct;134(10):2483-5. doi: 10.1038/jid.2014.294.

PMID:
25219647
12.

S-calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis.

Hansson C, Eriksson C, Alenius GM.

J Immunol Res. 2014;2014:696415. doi: 10.1155/2014/696415. Epub 2014 May 14.

13.

Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.

Glintborg B, Gudbjornsson B, Krogh NS, Omerovic E, Manilo N, Holland-Fischer M, Lindegaard HM, Loft AG, Nordin H, Johnsen L, Oeftiger SF, Hansen A, Rasmussen C, Grondal G, Geirsson AJ, Hetland ML.

Rheumatology (Oxford). 2014 Nov;53(11):2100-9. doi: 10.1093/rheumatology/keu252. Epub 2014 Jun 17.

PMID:
24939677
14.

Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study.

Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, Cohen JD, Coquerelle P, Goujon E, Jullien D, Brixi H, Jeudy G, Guennoc X, Martin A, Brénaut E, Hoppé E, Bertolotti A, Bardin T, Delaporte E, Allez M, Bachelez H, Seneschal J, Viguier M; Groupe de Recherche sur Psoriasis de Société Française de, Dermatologie; Club Rhumatismes et Inflammation (CRI); Groupe d'études thérapeutiques des affections inflammatoires du tube digestif (GETAID).

J Am Acad Dermatol. 2014 Jun;70(6):1146-9. doi: 10.1016/j.jaad.2014.03.005. No abstract available.

PMID:
24831323
15.

Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.

Hellgren K, Smedby KE, Backlin C, Sundstrom C, Feltelius N, Eriksson JK, Baecklund E, Askling J.

Arthritis Rheumatol. 2014 May;66(5):1282-90. doi: 10.1002/art.38339.

PMID:
24782185
16.

Varicella zoster virus encephalopathy in a patient with psoriatic arthritis treated with anti-TNFα agents.

Miyagi T, Yamaguchi S, Yamamoto Y, Ohira A, Yasumura R, Nakasone N, Uezato H, Takahashi K.

Eur J Dermatol. 2014 May-Jun;24(3):398-9. doi: 10.1684/ejd.2014.2331. No abstract available.

PMID:
24751487
17.

Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study.

Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon M, Balbi G, Ortolan A, Frallonardo P, Faggin E, Plebani M, Zaninotto M, Lorenzin M, Pauletto P, Doria A.

Joint Bone Spine. 2014 Oct;81(5):421-5. doi: 10.1016/j.jbspin.2014.02.005. Epub 2014 Apr 2.

PMID:
24703399
18.

Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis.

Guidelli GM, Tenti S, Fioravanti A.

Indian J Dermatol Venereol Leprol. 2014 Mar-Apr;80(2):187-9. doi: 10.4103/0378-6323.129422. No abstract available.

19.

Downregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.

Bergamini A, Chimenti MS, Baffari E, Guarino MD, Gigliucci G, Perricone C, Perricone R.

PLoS One. 2014 Mar 27;9(3):e92018. doi: 10.1371/journal.pone.0092018. eCollection 2014.

20.

Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis.

Bougea A, Anagnostou E, Stamboulis E, Kararizou E.

Rev Neurol (Paris). 2014 Mar;170(3):228-9. doi: 10.1016/j.neurol.2013.11.004. Epub 2014 Mar 18. No abstract available.

PMID:
24656415
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk